Analyzing host responses to respiratory viral infections in stem cell transplant patients
Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans
This study is trying to see if certain responses in the body can help predict if stem cell transplant patients will develop bronchiolitis obliterans after getting a respiratory infection from the parainfluenza virus.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 14 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT04099082 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between respiratory viral infections, specifically parainfluenza virus (PIV), and the development of bronchiolitis obliterans (BO) in patients who have undergone allogeneic hematopoietic stem cell transplantation. By analyzing blood and respiratory samples, the study seeks to identify specific host response signatures that may predict the occurrence of BO following a PIV infection. The research focuses on patients who have experienced respiratory infections within a defined timeframe and have documented evidence of PIV. The ultimate goal is to enhance understanding of the pathophysiology of BO and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults who have received a hematopoietic stem cell transplantation within the last two years and have a documented parainfluenza virus respiratory infection.
Not a fit: Patients with respiratory infections caused by viruses other than parainfluenza or those with bacterial or fungal infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better predictive tools for identifying patients at risk of developing bronchiolitis obliterans after respiratory viral infections.
How similar studies have performed: While the specific approach of this study may be novel, previous research has indicated a link between respiratory viral infections and complications in stem cell transplant patients, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Adults having received a hematopoietic stem cell transplantation for less than two years * Availability of respiratory function tests prior to infection * Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract * Symptoms of respiratory infection ≤ 5 days * Signed informed consent Exclusion Criteria: * Presence of a respiratory virus infection other than PIV * Viral respiratory co-infections * Bacterial or fungal respiratory infections * Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses * Patient not affiliated or beneficiary of a social security system * Patient deprived of liberty or protected * Pregnant or breastfeeding woman
Where this trial is running
Paris, Île-de-France Region
- Saint Louis — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Study coordinator: David Michonneau, MD PhD
- Email: david.michonneau@aphp.fr
- Phone: 1 42 49 49 49
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.